Activated Eosinophils
A drug approved to treat a severe form of asthma dramatically improved the health of people with rare chronic immune disorders called hypereosinophilic syndromes (HES) in whom other treatments were ineffective or intolerable. This finding comes from a small clinical trial led by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted through a partnership with the global biopharmaceutical company AstraZeneca. The results were published online on April 3, 2019 in the New England Journal of Medicine.
In this image: Activated eosinophils in the peripheral blood of a patient with idiopathic hypereosinophilic syndrome.
Read more: www.nih.gov/news-events/news-releases/fda-approved-drug-e...
Credit: National Institute of Allergy and Infectious Diseases/NIH
Activated Eosinophils
A drug approved to treat a severe form of asthma dramatically improved the health of people with rare chronic immune disorders called hypereosinophilic syndromes (HES) in whom other treatments were ineffective or intolerable. This finding comes from a small clinical trial led by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted through a partnership with the global biopharmaceutical company AstraZeneca. The results were published online on April 3, 2019 in the New England Journal of Medicine.
In this image: Activated eosinophils in the peripheral blood of a patient with idiopathic hypereosinophilic syndrome.
Read more: www.nih.gov/news-events/news-releases/fda-approved-drug-e...
Credit: National Institute of Allergy and Infectious Diseases/NIH